Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and pharmacokinetics of SHP465 in children aged 4 to 5 with ADHD; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SHP465 (SHP465)

Snippet

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 1 | Status: COMPLETED | Results posted: 2020-01-29